Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study
- PMID: 16226616
- DOI: 10.1016/S0140-6736(05)67568-X
Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study
Abstract
Background: Universal anti-hepatitis-B vaccination of infants and adolescents was implemented in Italy in 1991. We undertook a multicentre study in previously vaccinated individuals to assess the duration of immunity and need for booster, over 10 years after vaccination.
Methods: In 1212 children and 446 Italian Air Force recruits vaccinated as infants and adolescents, respectively, we measured the concentrations of antibodies to hepatitis-B surface antigen (anti-HBs) and the presence of antibodies to hepatitis-B core antigen (anti-HBc) at enrollment; postimmunisation values were not available. Individuals positive for anti-HBc were tested for hepatitis B surface antigen (HBsAg) and hepatitis B viral DNA. Individuals with anti-HBs concentrations at 10 IU/L or more were regarded as protected; those with antibody less than 10 IU/L were given a booster dose and retested 2 weeks later. Individuals showing postbooster anti-HBs concentrations of less than 10 IU/L were offered two additional vaccine doses and retested 1 month after the third dose.
Findings: Protective anti-HBs concentrations were retained in 779 (64%, 95% CI 61.6-67) children and 398 (89%, 86.4-92.1) recruits. We recorded antibody amounts of less than 10 IU/L in 433 children (36%, 33-38.4) and 48 (11%, 7.9-13.6) recruits. One child and four recruits were positive for anti-HBc, but negative for HBsAg and hepatitis B viral DNA. Antibody concentrations were higher in recruits than in children (geometric mean titre 234.8 IU/L vs 32.1 IU/L, p=0.0001). 332 (97%) of 342 children and 46 (96%) of 48 recruits who received a booster showed an anamnestic response, whereas ten (3%) children and two (4%) recruits remained negative for anti-HBs or had antibody concentrations of less than 10 IU/L. Prebooster and postbooster antibody titres were strongly correlated with each other in both groups. All individuals given two additional vaccine doses (eight children and two recruits) showed anti-HBs amounts of more than 10 IU/L at 1 month after vaccination.
Interpretation: Strong immunological memory persists more than 10 years after immunisation of infants and adolescents with a primary course of vaccination. Booster doses of vaccine do not seem necessary to ensure long-term protection.
Comment in
-
Hepatitis B vaccination: to boost or not to boost?Lancet. 2005 Oct 15-21;366(9494):1337-8. doi: 10.1016/S0140-6736(05)67544-7. Lancet. 2005. PMID: 16226597 No abstract available.
Similar articles
-
Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study.Lancet Infect Dis. 2010 Nov;10(11):755-61. doi: 10.1016/S1473-3099(10)70195-X. Epub 2010 Sep 29. Lancet Infect Dis. 2010. PMID: 20884297 Clinical Trial.
-
Persistence of anti-HBs antibody and immunological memory in children vaccinated with hepatitis B vaccine at birth.J Ayub Med Coll Abbottabad. 2006 Oct-Dec;18(4):4-9. J Ayub Med Coll Abbottabad. 2006. PMID: 17591001
-
Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study.Pediatr Infect Dis J. 2008 Oct;27(10):881-5. doi: 10.1097/INF.0b013e31817702ba. Pediatr Infect Dis J. 2008. PMID: 18756185
-
Booster dose vaccination for preventing hepatitis B.Cochrane Database Syst Rev. 2016 Jun 7;2016(6):CD008256. doi: 10.1002/14651858.CD008256.pub3. Cochrane Database Syst Rev. 2016. PMID: 27271960 Free PMC article. Review.
-
Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity.Lancet. 2000 Feb 12;355(9203):561-5. Lancet. 2000. PMID: 10683019 Review.
Cited by
-
Persistence of hepatitis B surface antibody until 7 years of age following administration of hexavalent and pentavalent vaccines in children at 2, 4, 6, and 18 months.Vaccine X. 2024 Sep 20;20:100561. doi: 10.1016/j.jvacx.2024.100561. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39385752 Free PMC article.
-
Incidence of Low Seroimmunity to Hepatitis B Virus in Children with Inflammatory Bowel Disease: A Single Center Experience.Pediatr Gastroenterol Hepatol Nutr. 2024 Mar;27(2):104-112. doi: 10.5223/pghn.2024.27.2.104. Epub 2024 Mar 4. Pediatr Gastroenterol Hepatol Nutr. 2024. PMID: 38510586 Free PMC article.
-
Long-Term Hepatitis B Vaccine Immunity in Ethiopian Children That Received a Pentavalent Vaccine Series: A Retrospective Cohort Study.Children (Basel). 2024 Jan 22;11(1):136. doi: 10.3390/children11010136. Children (Basel). 2024. PMID: 38275446 Free PMC article.
-
Protective Anti-HBs Antibodies and Response to a Booster Dose in Medical Students Vaccinated at Childhood.Vaccines (Basel). 2023 Aug 5;11(8):1326. doi: 10.3390/vaccines11081326. Vaccines (Basel). 2023. PMID: 37631894 Free PMC article.
-
Hepatitis B virus vaccination post serological testing and antibody levels of vaccinated health care workers in Accra, Ghana.Vaccine X. 2023 Apr 3;14:100294. doi: 10.1016/j.jvacx.2023.100294. eCollection 2023 Aug. Vaccine X. 2023. PMID: 37101844 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
